Clik here to view.
Rapid Medical的DISTALS中风试验首位患者入组——为新发缺血性中风患者群体提供治疗
以色列约克尼穆与迈阿密 (美国商业资讯)–先进神经血管器械的领先开发商Rapid Medical今天宣布，DISTALS研究的首位患者已经入组。该试验是美国食品药品管理局(FDA)有史以来第一个研究机械血栓切除术在远端中风中的安全性和有效性的试验用器械豁免(IDE)试验。 德国索林根radprax Neurocenter神经放射科主任Hannes...
View ArticleClik here to view.
athenahealth and Smile Foundation Partnership Reaches Key Milestone
WATERTOWN, Mass. athenahealth, Inc., a leading provider of network-enabled software and services for medical groups and health systems nationwide, and Smile Foundation today announced that through...
View ArticleClik here to view.
The Lancet Publication Shows Benefits of PharmaJet Needle-free delivery for...
GOLDEN, Colo. PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced that...
View ArticleClik here to view.
WittKieffer Life Sciences Practice Expands Global Capabilities
OAK BROOK, Ill. WittKieffer, a leading global executive search and advisory firm dedicated to improving quality of life through impactful leadership, today announced the expansion of its global Life...
View ArticleClik here to view.
OliX Pharmaceuticals to Conduct Business Meetings with Potential Partners at...
SUWON, South Korea OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will participate in one-on-one partnering...
View ArticleClik here to view.
NTT DATA Improves Independent Health’s IT Experience for Employees,...
PLANO, Texas Together with NTT DATA, Independent Health has transformed its IT infrastructure services, building an end-to-end model that speeds response time, allows for predictive and proactive...
View ArticleClik here to view.
ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales...
LOS ANGELES ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced a signed distribution agreement with Sinopharm Xingsha to accelerate...
View ArticleClik here to view.
China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and...
View ArticleClik here to view.
フェリングがオラムキセプトの開発で新たな連携を発表
スイス・サンプレ （ビジネスワイヤ） — フェリング・ファーマシューティカルズは本日、炎症性腸疾患（IBD）および関連炎症性疾患におけるオラムキセプトのさらなる開発に向けて、I-Mabと戦略的提携関係を構築したと発表しました。...
View ArticleClik here to view.
辉凌医药宣布新的Olamkicept开发合作关系
瑞士圣普雷克斯 (美国商业资讯)–辉凌医药(Ferring Pharmaceuticals)今天宣布与I-Mab达成战略合作，进一步开发olamkicept在炎性肠病(IBD)和相关炎症中的应用。...
View ArticleClik here to view.
Quizartinib Plus Chemotherapy Significantly Improved Overall Survival...
TOKYO & BASKING RIDGE, N.J. Positive results from the global pivotal QuANTUM-First phase 3 trial of Daiichi Sankyo’s (TSE:5468) quizartinib combined with standard induction and consolidation...
View ArticleClik here to view.
BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and...
View ArticleClik here to view.
BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and...
View ArticleClik here to view.
Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture
PALO ALTO, Calif. Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it has purchased the remaining shares of Guardant Health AMEA, Inc., held by SoftBank and...
View ArticleClik here to view.
Organon Enters into Global License Agreement to Commercialize Henlius’...
JERSEY CITY, N.J. Organon (NYSE: OGN), a global women’s health company with deep expertise in biosimilar commercialization, today announced that it has entered into an agreement with Shanghai...
View ArticleClik here to view.
Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with...
SEOUL, South Korea Genexine (KOSDAQ: 095700) a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet...
View ArticleClik here to view.
Synopsis on the 1st IOF International Orthodontic Symposium
HONG KONG Orthodontics is the art of health and aesthetics that follows nature and portrays our pursuit of beauty. For thousands of years, orthodontists – the engineers and artists of orthodontics –...
View ArticleClik here to view.
Exscientia报告健康志愿者1a期研究的顶线数据，表明EXS-21546可靶向抑制A2A受体信号传导
英格兰牛津 (美国商业资讯)–Exscientia plc (Nasdaq: EXAI)今天发布其EXS-21546 1期健康志愿者研究数据。EXS-21546是由Exscientia和Evotec SE（法兰克福证券交易所：EVT,...
View ArticleClik here to view.
Guardant Health完成了对Guardant Health AMEA合资公司的收购
加州帕洛阿托 (美国商业资讯)–领先的精准肿瘤医学公司Guardant Health, Inc. (NASDAQ:GH)今天宣布，其已收购软银及其附属公司持有的Guardant Health AMEA, Inc.的剩余股份，从而使公司获得了对整个亚洲、中东和非洲(AMEA)地区业务的全面掌控。 据估计，世界上超过一半的新发癌症病例来自亚洲、中东和非洲(AMEA)。1此次收购将让Guardant...
View ArticleClik here to view.
ガーダントヘルスが合弁会社Guardant Health AMEAの買収を完了
米カリフォルニア州パロアルト （ビジネスワイヤ） — がん精密医療の大手企業であるガーダントヘルス（NASDAQ:GH）は本日、ソフトバンクとその関連会社が保有するGuardant Health AMEA, Inc.の残りの株式を購入し、アジア・中東・アフリカ地域全体の事業を完全に掌握したと発表しました。...
View Article